JMK has received funds for research support from H. Lundbeck, Janssen, and Otsuka; has received consulting fees or honoraria for lectures from Alkermes, Biogen, Boehringer Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HLS, Indivior, Intra-Cellular Therapies, Janssen, Johnson and Johnson, Karuna, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Neumora, Newron, Novartis, Otsuka, Reviva, Roche, Saladax, Sunovion, Takeda, and Teva; and has ownership interest in HealthRhythms, North Shore Therapies, LB Pharmaceuticals, Medincell, and the Vanguard Research Group. TK reports consultant fees from Boehringer-Ingelheim, Chugai, Sumitomo Dainippon, I’mbesideyou, Otsuka, TechDoctor, speaker's honoraria from Eli Lilly, Daiichi-Sankyo, Eisai, Sumitomo Dainippon, Janssen, Novartis, Otsuka, Pfizer, grant support from Otsuka, Sumitomo Dainippon, and being a founder of i2medical, and receiving donation course from Mori building, outside the submitted work. EA has served on advisory boards for Alkermes, Atheneum, Indivior, Karuna, Lundbeck, Otsuka, Neurocrine Biosciences, Sunovion, Teva; has received research support of Alkermes, Astellas, Biogen, Boehringer-Ingelheim, InnateVR, Janssen, Lundbeck, National Network of Depression Centers, Neurocrine Biosciences, Otsuka, Pear Therapeutics, Takeda. JR has consulted for Janssen, TEVA, and Karuna, received royalties from UpToDate and received research support from NIMH, Alkermes and Saladax. CC has been a consultant and/or advisor to, or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris, and has provided expert testimony for Janssen and Otsuka. CC served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva, has received grant support from Janssen and Takeda, royalties from UpToDate, and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma, and Quantic.